ReviewGlobal health & medicine2019
Challenges to eliminating the AIDS pandemic in China.
Review in Global health & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving Challenges in the Implementation of China's "Four Frees and One Care" Policy for HIV/AIDS.Risk management and healthcare policy · 2024Article
- Impact of the COVID-19 pandemic and the dynamic COVID-zero strategy on HIV incidence and mortality in China.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on data from the Chinese Center for Disease Control and Prevention (CDC), there were a total of 861,042 people with human immunodeficiency virus (HIV)/ immune deficiency syndrome (AIDS) as of December 31, 2018 in China, a total of 148,589 new HIV infections, and 38,134 AIDS-related deaths in the year 2018. As of 2017, only 74% of people living with HIV knew their status, 80% of people living with HIV were receiving treatment, and 91% were virally suppressed in China. Although mankind has made great progress in the fight against AIDS in recent years, the vision of ending the AIDS epidemic still faces many challenges in China. Due to the huge population and the imbalance in the prevalence of HIV/AIDS in China, expanding HIV screening and early detection remains the key to Chinas response to HIV. Limitations of antiviral therapy (ART), rejection or discontinuation of an immediate ART strategy by people infected with HIV, and the difficult search for a cure for AIDS all limit the coverage and quality of treatment. The high price of drugs and lack of vaccines present enormous challenges; social discrimination still exists, and participation by non-governmental organizations in prevention, treatment, and care is limited. As part of the future response to HIV, HIV eradication programs should continue to be explored, and attention should be paid to long-term care for people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.